| CAS ID: | 52-01-7 |
| Molecular Formula: | C24H32O4S |
| Molecular Weight: | 416.6 g/mol |
| Monoisotopic Mass: | 416.2021 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | SPIROSPARE 25 | SPIROCTAN 25 | SPIROCTAN 100 | CAROSPIR | ABBOLACTONE | SPIROSPARE 100 | GX SPIRONOL | LARACTONE | ALDACTONE | DIATENSEC | SPIRETIC | SPIRONOLACTONE | SPIROCTAN 50 |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1 | See All |
| InChI Key: | LXMSZDCAJNLERA-ZHYRCANASA-N | |
| Smiles: | CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13 | See All |
| Molfile: | Download |
| Target ID | Name | Interaction |
|---|---|---|
| T0536 | Mineralocorticoid receptor | antagonist |
| T1052 | Aldosterone | antagonist |
Reference Record 1
| PubMed ID | 27221077 | Target ID | |
| Uniprot ID | Name | ||
| Model | mice | Fibrosis Disease | Pulmonary fibrosis |
| Process I | attenue inflammation | ||
| Process II | |||
| Process III | |||
| Mechanism | |||
Reference Record 2
| PubMed ID | 26136067 | Target ID | |
| Uniprot ID | Name | ||
| Model | rat | Fibrosis Disease | Vascular fibrosis |
| Process I | |||
| Process II | |||
| Process III | |||
| Mechanism | |||
Reference Record 3
Reference Record 4
| PubMed ID | 24260540 | Target ID | |
| Uniprot ID | Name | ||
| Model | mice | Fibrosis Disease | Pulmonary fibrosis |
| Process I | attenue inflammation | ||
| Process II | |||
| Process III | prevenet collagen deposition | ||
| Mechanism | |||
Reference Record 5
Reference Record 6
Reference Record 7
Reference Record 8
Reference Record 9
| PubMed ID | 11592866 | Target ID | |
| Uniprot ID | Name | ||
| Model | rat | Fibrosis Disease | Cardiac fibrosis |
| Process I | |||
| Process II | |||
| Process III | prevenet collagen deposition | ||
| Mechanism | |||
Trial Record 1
| ClinicalTrial ID | NCT00879060 | Disease | Cardiac fibrosis |
| Phase | Phase 4 | Status | Unknown |
| First Received | April 9, 2009 | Last Verified | April 9, 2009 |
| Sponsor | Tufts Medical Center | ||
Trial Record 2
| ClinicalTrial ID | NCT00879060 | Disease | Cardiac fibrosis |
| Phase | Phase 4 | Status | Unknown |
| First Received | April 9, 2009 | Last Verified | April 9, 2009 |
| Sponsor | Tufts Medical Center | ||
Trial Record 3
| ClinicalTrial ID | NCT00865449 | Disease | Renal fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | March 19, 2009 | Last Verified | October 25, 2012 |
| Sponsor | Instituto Nacional de Cardiologia Ignacio Chavez | ||
Trial Record 4
| ClinicalTrial ID | NCT02764619 | Disease | Cardiac fibrosis |
| Phase | Phase 3 | Status | Unknown |
| First Received | May 6, 2016 | Last Verified | May 17, 2016 |
| Sponsor | Svendborg Hospital | ||
Trial Record 5
| ClinicalTrial ID | NCT02907749 | Disease | Liver fibrosis |
| Phase | Phase 4 | Status | Recruiting |
| First Received | September 20, 2016 | Last Verified | October 10, 2017 |
| Sponsor | Changqing Yang | ||
Trial Record 6
| ClinicalTrial ID | NCT01069510 | Disease | Cardiac fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | February 17, 2010 | Last Verified | April 6, 2017 |
| Sponsor | Oregon Health and Science University | ||
Trial Record 7
| ClinicalTrial ID | NCT02948998 | Disease | Cardiac fibrosis |
| Phase | Phase 4 | Status | Not yet recruiting |
| First Received | October 31, 2016 | Last Verified | May 9, 2018 |
| Sponsor | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | ||
Trial Record 8
| ClinicalTrial ID | NCT02673463 | Disease | Cardiac fibrosis |
| Phase | Phase 4 | Status | Active, not recruiting |
| First Received | February 4, 2016 | Last Verified | October 11, 2018 |
| Sponsor | University of Birmingham | ||
Trial Record 9
| ClinicalTrial ID | NCT00188045 | Disease | Liver fibrosis |
| Phase | Phase 4 | Status | Terminated |
| First Received | September 16, 2005 | Last Verified | November 1, 2017 |
| Sponsor | University Hospital, Angers | ||
Trial Record 10
| ClinicalTrial ID | NCT01801228 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Withdrawn |
| First Received | February 28, 2013 | Last Verified | January 15, 2016 |
| Sponsor | Emma Nilsson | ||
Trial Record 11
| ClinicalTrial ID | NCT00741663 | Disease | Liver fibrosis |
| Phase | Phase 4 | Status | Completed |
| First Received | August 26, 2008 | Last Verified | September 25, 2008 |
| Sponsor | University of Padova | ||
Trial Record 12
| ClinicalTrial ID | NCT00332904 | Disease | Liver fibrosis |
| Phase | Phase 4 | Status | Unknown |
| First Received | June 2, 2006 | Last Verified | June 4, 2010 |
| Sponsor | Hvidovre University Hospital | ||
Trial Record 13
| ClinicalTrial ID | NCT01021943 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Suspended |
| First Received | December 1, 2009 | Last Verified | July 24, 2014 |
| Sponsor | Instituto Nacional de Cardiologia Ignacio Chavez | ||
Trial Record 14
| ClinicalTrial ID | NCT01602861 | Disease | Renal fibrosis |
| Phase | Phase 4 | Status | Unknown |
| First Received | May 21, 2012 | Last Verified | January 24, 2014 |
| Sponsor | Odense University Hospital | ||
Trial Record 15
| ClinicalTrial ID | NCT02285920 | Disease | Renal fibrosis |
| Phase | Phase 2 | Status | Active, not recruiting |
| First Received | November 7, 2014 | Last Verified | August 7, 2018 |
| Sponsor | University of Pennsylvania | ||
Trial Record 16
| ClinicalTrial ID | NCT00663195 | Disease | Cardiac fibrosis |
| Phase | Phase 4 | Status | Completed |
| First Received | April 22, 2008 | Last Verified | April 22, 2008 |
| Sponsor | Tottori University Hospital | ||
| PubChem: | 5833 |
| ChEMBL: | CHEMBL1393 |